Literature DB >> 14500674

Inhibition of cytokine gene transcription by the human recombinant histamine-releasing factor in human T lymphocytes.

Becky M Vonakis1, Rebecca Sora, Jacqueline M Langdon, Vincenzo Casolaro, Susan M MacDonald.   

Abstract

Human recombinant histamine-releasing factor (HrHRF) preincubation enhances the secretion of histamine, IL-4, and IL-13 from FcepsilonRI-stimulated human basophils. In GM-CSF-primed human eosinophils, HrHRF increases IL-8 production. Our recent experiments were designed to evaluate the effects of HrHRF on human T cell cytokine production. Purified T cells were preincubated with GST-tagged HrHRF, followed by stimulation with PMA and A23187 overnight. A partial inhibition of IL-2 and IL-13 production (30 and 75%, respectively) was detected compared with that in cells treated with PMA/A23187 alone. However, the production of IFN-gamma was similar in PMA/A23187 stimulated cells with or without HrHRF. The inhibition of cytokine protein production was dose dependent and specific to the HrHRF portion of GST-HrHRF. The inhibition was not due to endotoxin, since preincubation with polymyxin B and HrHRF gave similar results to that with HrHRF alone. The same pattern and specificity of cytokine regulation were replicated in the Jurkat T cell line as for primary T cells. The PMA/A23187-stimulated activity of a proximal promoter IL-13, IL-4, or IL-2 luciferase construct transfected into Jurkat cells was partially inhibited (60, 32, or 70%, respectively) upon GST-HrHRF preincubation, suggesting that HrHRF functions to inhibit cytokine production in Jurkat cells by preventing gene transcription. The inhibition of IL-2 promoter activation was specific to the HrHRF portion of GST-HrHRF. We conclude that HrHRF, in addition to functioning as a histamine-releasing factor, can differentially modulate the secretion of cytokines from human basophils, eosinophils, T cells, and murine B cells, suggesting that it may induce a complex array of responses at sites of allergic inflammation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14500674     DOI: 10.4049/jimmunol.171.7.3742

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity.

Authors:  Yu Yang; Fan Yang; Zeyu Xiong; Yan Yan; Xinmen Wang; Michiya Nishino; Dragan Mirkovic; Justin Nguyen; Hong Wang; Xiao-Feng Yang
Journal:  Oncogene       Date:  2005-07-14       Impact factor: 9.867

2.  Histamine in pericarditis of children with congenital heart malformations.

Authors:  D Maslińska; M Laure-Kamionowska; P Rzodkiewicz; E Lukasik-Wojtecka; D Szukiewicz; M Karolczak; S Masliński
Journal:  Inflamm Res       Date:  2010-03       Impact factor: 4.575

3.  The effects of overexpression of histamine releasing factor (HRF) in a transgenic mouse model.

Authors:  Yueh-Chiao Yeh; Liping Xie; Jacqueline M Langdon; Allen C Myers; Sun-Young Oh; Zhou Zhu; Susan M Macdonald
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

4.  Histamine-releasing factor/translationally controlled tumor protein (HRF/TCTP)-induced histamine release is enhanced with SHIP-1 knockdown in cultured human mast cell and basophil models.

Authors:  Jacqueline M Langdon; John T Schroeder; Becky M Vonakis; Anja P Bieneman; Kristin Chichester; Susan M Macdonald
Journal:  J Leukoc Biol       Date:  2008-07-14       Impact factor: 4.962

5.  Distinct characteristics of signal transduction events by histamine-releasing factor/translationally controlled tumor protein (HRF/TCTP)-induced priming and activation of human basophils.

Authors:  Becky M Vonakis; Donald W Macglashan; Natalia Vilariño; Jacqueline M Langdon; Rebecca S Scott; Susan M MacDonald
Journal:  Blood       Date:  2007-11-27       Impact factor: 22.113

6.  Potential role of histamine releasing factor (HRF) as a therapeutic target for treating asthma and allergy.

Authors:  Susan M Macdonald
Journal:  J Asthma Allergy       Date:  2012-09-17

Review 7.  Histamine-releasing factor and immunoglobulins in asthma and allergy.

Authors:  Toshiaki Kawakami; Jun-Ichi Kashiwakura; Yuko Kawakami
Journal:  Allergy Asthma Immunol Res       Date:  2013-07-02       Impact factor: 5.764

8.  Dimerization of translationally controlled tumor protein is essential for its cytokine-like activity.

Authors:  Miyoung Kim; Hyun Jung Min; Hee Yeon Won; Heejin Park; Ji-Chul Lee; Heung-Woo Park; Junho Chung; Eun Sook Hwang; Kyunglim Lee
Journal:  PLoS One       Date:  2009-07-31       Impact factor: 3.240

9.  Translationally controlled tumour protein (TCTP) is present in human cornea and increases in herpetic keratitis.

Authors:  Cinzia Batisti; Maria R Ambrosio; Bruno J Rocca; Gian M Tosi; Jean C Sanchez; Felice Arcuri; Marcella Cintorino; Sergio A Tripodi
Journal:  Diagn Pathol       Date:  2012-08-01       Impact factor: 2.644

10.  Binding of Translationally Controlled Tumour Protein to the N-terminal domain of HDM2 is inhibited by nutlin-3.

Authors:  Garth Funston; Walter Goh; Siau Jia Wei; Quah Soo Tng; Christopher Brown; Loh Jiah Tong; Chandra Verma; David Lane; Farid Ghadessy
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.